Journal article · 2024 · Open access

CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence

John K. Bui, Carly E. Starke, Nikhita H. Poole, Blake J. Rust, Keith R. Jerome, Hans‐Peter Kiem, Christopher W. Peterson

Molecular Therapy, 32(5), 1238–1251 · Published 26 February 2024 · DOI 10.1016/j.ymthe.2024.02.030

Open PDFView at the publisherCite this paper

In brief

“CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence” is a 2024 journal article by John K. Bui and 6 co-authors, published in Molecular Therapy. OpenAlex counts 18 citations as of 19 November 2026, which puts it in the top 2% of works published in 2024 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Molecular Therapy.

Citations
18
Most cited in
2026 (11)
Field-weighted impact
2.64
References
49
Authors
7

Abstract

Chimeric antigen receptor (CAR) T cell therapies have demonstrated immense clinical success for B cell and plasma cell malignancies. We tested their impact on the viral reservoir in a macaque model of HIV persistence, comparing the functions of CD20 CAR T cells between animals infected with simian/human immunodeficiency virus (SHIV) and uninfected controls. We focused on the potential of this approach to disrupt B cell follicles (BCFs), exposing infected cells for immune clearance. In SHIV-infected animals, CAR T cells were highly functional, with rapid expansion and trafficking to tissue-associated viral sanctuaries, including BCFs and gut-associated lymphoid tissue (GALT). CD20 CAR T cells potently ablated BCFs and depleted lymph-node-associated follicular helper T (T FH ) cells, with complete restoration of BCF architecture and T FH cells following CAR T cell contraction. BCF ablation decreased the splenic SHIV reservoir but was insufficient for effective reductions in systemic viral reservoirs. Although associated with moderate hematologic toxicity, CD20 CAR T cells were well tolerated in SHIV-infected and control animals, supporting the feasibility of this therapy in people living with HIV with underlying B cell malignancies. Our findings highlight the unique ability of CD20 CAR T cells to safely and reversibly unmask T FH cells within BCF sanctuaries, informing future combinatorial HIV cure strategies designed to augment antiviral efficacy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Bui, J. K., Starke, C. E., Poole, N. H., Rust, B. J., Jerome, K. R., Kiem, H., & Peterson, C. W. (2024). CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence. Molecular Therapy, 32(5), 1238–1251. https://doi.org/10.1016/j.ymthe.2024.02.030

MLA 9

Bui, John K., et al. “CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence.” Molecular Therapy, vol. 32, no. 5, 2024, pp. 1238–1251. https://doi.org/10.1016/j.ymthe.2024.02.030.

Chicago

Bui, John K., Carly E. Starke, Nikhita H. Poole, Blake J. Rust, Keith R. Jerome, Hans‐Peter Kiem, and Christopher W. Peterson. 2024. “CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence.” Molecular Therapy 32 (5): 1238–1251. https://doi.org/10.1016/j.ymthe.2024.02.030.

Harvard

Bui, J. K. et al. (2024) ‘CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence’, Molecular Therapy, 32(5), pp. 1238–1251. doi:10.1016/j.ymthe.2024.02.030.

IEEE

J. K. Bui et al., “CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence,” Molecular Therapy, vol. 32, no. 5, pp. 1238–1251, 2024, doi: 10.1016/j.ymthe.2024.02.030.

BibTeX

@article{bui2024cells,
  title     = {{CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence}},
  author    = {Bui, John K. and Starke, Carly E. and Poole, Nikhita H. and Rust, Blake J. and Jerome, Keith R. and Kiem, Hans‐Peter and Peterson, Christopher W.},
  journal   = {Molecular Therapy},
  year      = {2024},
  volume    = {32},
  number    = {5},
  pages     = {1238--1251},
  doi       = {10.1016/j.ymthe.2024.02.030},
  url       = {https://doi.org/10.1016/j.ymthe.2024.02.030}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › CAR-T cell therapy research

  • HIV persistence
  • viral reservoir
  • B cell follicles
  • T follicular helper cells
  • SHIV
  • macaque model
  • gut-associated lymphoid tissue
  • HIV cure

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Bui, J. K., Starke, C. E., Poole, N. H., Rust, B. J., Jerome, K. R., Kiem, H., & Peterson, C. W. (2024). CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence. Molecular Therapy, 32(5), 1238–1251. https://doi.org/10.1016/j.ymthe.2024.02.030

How many times has this paper been cited?

18 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Molecular Therapy: sign in and open the PDF from this page.

Who wrote this paper?

John K. Bui, Carly E. Starke, Nikhita H. Poole, Blake J. Rust, Keith R. Jerome, Hans‐Peter Kiem, Christopher W. Peterson.

What is the DOI of this paper?

10.1016/j.ymthe.2024.02.030, permanently at https://doi.org/10.1016/j.ymthe.2024.02.030. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.